The present invention relates to agents for the treatment and/or diagnosis of endometriosis and other benign gynecological neoplasms disease or disorder and also relates to agents capable of eliciting a cytotoxic response in benign gynecological neoplasms diseases or disorders.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
SpSpCas9 nickase fused to an engineered Moloney Murine leukaemia virus (M-MLV) reverse transcriptase, characterized by a mutation, relative to a reference sequence SEQ ID NO 001, selected from the group consisting of A277D; K1865T; and S237A. Another aspect of the invention relates to a combination of a first and second split PE variant polypeptide comprising split intein component at its C- and N-terminus, respectively, which, when both are present within a target cell, are capable of forming a fusion polypeptide comprising a functional prime editing polypeptide according to the first aspect of the invention. Other aspects of the invention relate to a combination medicaments and nucleic acid sequences facilitating the PE variant of the invention.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable electronic publications; electronic
(downloadable) publications available from databases or the
Internet; recorded software; scientific apparatus and
instruments. Publication of specialized scientific-information journals;
electronic desktop publishing; electronic publishing
services; provision of non-downloadable electronic
publications online; online publication of specialized
electronic books and journals; publication services;
training; education, teaching and training; education and
training in the field of electronic data processing;
organization and conducting of colloquiums; organization and
conducting of training workshops; organization and
conducting of seminars; organization and conducting of
symposiums; teaching; academies (education); correspondence
courses; publication of texts other than advertising texts;
organization and conducting of conferences; organization and
conducting of congresses; publication of evidence-based
recommendations (policy briefs). Services provided by consultants in the field of scientific
and industrial research; consultant services with respect to
technical and scientific analysis; services provided by
consultants relating to technical and scientific
measurements; consultant services with respect to technical
and scientific controls; providing information and data with
respect to scientific and technological research and
development; computer-aided scientific analysis services;
computer-aided scientific research services; computer-aided
scientific research, testing and analysis services;
conducting of scientific studies; preparation of scientific
reports; preparation of reports relating to scientific
research; research, testing and analysis services; providing
technical advice in the field of scientific and industrial
research; scientific analyses; scientific data analysis;
scientific research; scientific research in the field of
genetics; research and design services; scientific research
and development; scientific research conducted using
databases and the Internet; scientific research, testing and
analysis services; scientific and industrial research
services; scientific and technological services; scientific
and technological services as well as research and design
services relating thereto; provision of computer programs on
data networks; analysis of technical data; creation and
development of computer programs for data processing;
development of programs for data processing; programming of
electronic data processing (EDP) software; programming of
data calculation and evaluation software; design,
development, maintenance and updating of data processing
software.
The present invention relates to a composition for use in treating a condition of the lower gastrointestinal tract, e.g. ulcerative colitis, wherein the composition comprises: a) a carrier comprising: a1) water in an amount of more than 10% to 30% by weight of the carrier; and a2) monoacylglycerol lipid in an amount of 70% to 90% by weight of the carrier, wherein the monoacylglycerol lipid comprises monolinolein or monoolein, or combinations thereof; and b) a pharmaceutically active agent, wherein the composition forms a lipid cubic phase at a temperature of 36° C. to 39° C. The composition is particularly suitable for rectal administration, for example, as an enema. Also disclosed is a composition, methods for preparing the compositions, and kits for making the compositions.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
5.
Adenoviral Mediated Targeting of Activated Immune Cells
Disclosed herein are recombinant adenoviruses, recombinant proteins and trimeric proteins that are useful for the transduction of immune cells, such as T cells or NK cells. The present invention provides a versatile and highly specific system that is useful for numerous purposes, including the development of novel therapeutic approaches. The present invention makes use of specially designed adapter molecules that enable the specific targeting of immune cells, such as T cells or NK cells, which strongly increases transduction efficiencies, in particular for in vitro transduction of immune cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
6.
COMPUTER SYSTEM AND METHOD FOR CALCIUM CITRATE HEMOFILTER DECISION SUPPORT
To monitor a clinical state of a patient during calcium citrate hemofilter therapy, blood gas analysis sensor data is received as time series of sampled measurement values for the patient's blood gas state parameters, and, time series of continuous measurement values for calcium citrate hemofilter state parameters are received. Each blood gas analysis state parameter is mapped to predefined calcium citrate hemofilter adjustment reference tables defining whether a parameter is within a normal range, and generating one or more therapy adjustment suggestion outputs based on one or more of the blood gas analysis state parameters. Each state parameter is mapped to a predefined corresponding graphical representation. A virtual scene representation is rendered representing the inside of a blood filled hemofilter catheter representing blood flowing through the hemofilter. Thereby, animated visualizations of the graphical representations reflect current values of the respective state parameters and the generated therapy adjustment suggestion outputs.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
The invention relates to a method for determining the prognosis of a patient diagnosed with cancer, the method comprising: - obtaining from the patient a histology section containing a tumour area; - in a measurement step, contacting the histology section with a labelled probe capable of specifically labelling T cells, and obtaining an image of the tumour area, - in an image analysis step, quantifying the density of T cells present per mm2 in at least 2 separate, non-overlapping regions of the image of the tumour area; - calculating a dispersion value (alpha); and - assigning the patient a high probability of survival if the dispersion value is below a threshold value; or a low probability of survival if the dispersion value is above the threshold value.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The disclosed rod bending device (1) is intended for bending a rod (3) according to an anatomy of a patient, said rod intended for stabilizing a spine of the patient. The rod bending device comprises a chuck (2), configured to receive and temporarily hold a first end (31) of the rod to be bent according to the anatomy of the patient, said chuck being arranged rotatably about a first axis (Y) driven by an electric rotation motor (4). The rod bending device comprises an electric linear displacement motor (5) configured to displace the chuck relative to a bending head (7) in the direction of the first axis. The rod bending device comprises said bending head comprising a first abutment (71) and a thereto relatively moveable second abutment (72) driven by an electric bending motor (6) to bend the rod around a bending edge (74) arranged at the first abutment.
A device for repair surgery of cylindrical organs, particularly of ruptured tendons, is configured as a tubular sheath (T) made of a mesh of elastic fibers formed by electrospinning biocompatible and biodegradable polymers. The tubular sheath has a first, inner wall surface and a second,outer wall surface substantially parallel thereto, with said first wall surface being comparatively rough (WR) and said second wall surface being comparatively smooth (WS).
The disclosure relates to novel TSTA-3 and/or RASGRP2 peptides and a combination and a polypeptide or protein comprising such peptides. The peptides or polypeptides or proteins can particularly be used for the treatment and/or prevention of multiple sclerosis (MS), such as in a tolerization approach.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
11.
Perfusion Loop Assembly for an Ex-Vivo Liver Perfusion and a Method for Ex-Vivo Liver Perfusion
A perfusion loop assembly for ex vivo liver perfusion includes a pump providing perfusion fluid through a line branching at a branching point into a first branch line and a second branch line. The first branch line provides a first portion of the perfusion fluid to the hepatic artery of the liver, the first branch line coupled with a gas exchanger, where the first branch line includes a flow rate sensor and/or a pressure sensor. The second branch line provides a second portion of the perfusion fluid to the portal vein of the liver; the second branch line includes a valve for controlling flow of perfusion fluid into the portal vein. The second branch line includes a flow rate sensor and/or a pressure sensor. A liver chamber assembly holds the liver ex vivo, and an outlet line for the perfusion fluid connects the liver chamber assembly and the pump.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Publications électroniques téléchargeables; publications électroniques (téléchargeables) disponibles à partir de bases de données ou d'Internet; logiciels enregistrés; appareils et instruments scientifiques. (1) Publication de revues spécialisées d'information scientifique; micro-édition; services de publication électronique; mise à disposition de publications électroniques en ligne non téléchargeables; publication en ligne de livres et revues spécialisées électroniques; services de publication; formation; éducation, enseignement et formation; éducation et formation dans le domaine du traitement électronique de données; organisation et conduite de colloques; organisation et conduite d'ateliers de formation; organisation et conduite de séminaires; organisation et conduite de symposiums; enseignement; académies (éducation); enseignement par correspondance; publication de textes autres que textes publicitaires; organisation et conduite de conférences; organisation et conduite de congrès; publication de recommandations fondées sur des données probantes (policy briefs).
(2) Services de conseillers dans le domaine de la recherche scientifique et industrielle; services de conseillers en matière d'analyses techniques et scientifiques; services de conseillers en matière de mesurages techniques et scientifiques; services de conseillers en matière de contrôles techniques et scientifiques; mise à disposition d'informations et de données en matière de recherche et développement scientifiques et technologiques; services d'analyses scientifiques assistées par ordinateur; services de recherches scientifiques assistées par ordinateur; services de recherches, d'essais et d'analyses scientifiques assistés par ordinateur; réalisation d'études scientifiques; préparation de rapports scientifiques; préparation de rapports en matière de recherches scientifiques; services d'analyse, d'essai et de recherche; prestation de conseils techniques dans le domaine de la recherche scientifique et industrielle; analyses scientifiques; analyse de données scientifiques; recherches scientifiques; recherches scientifiques dans le domaine de la génétique; services de recherche et conception; recherche et développement scientifiques; recherches scientifiques réalisées à l'aide de bases de données et d'Internet; services de recherches, d'essais et d'analyses scientifiques; recherches scientifiques et industrielles; services scientifiques et technologiques; services scientifiques et technologiques ainsi que services de recherches et de conception y relatifs; mise à disposition de programmes informatiques sur des réseaux de données; analyses de données techniques; création et développement de programmes informatiques pour le traitement de données; développement de programmes de traitement de données; programmation de logiciels de traitement électronique de données (ted); programmation de logiciels d'évaluation et de calcul de données; conception, développement, maintenance et mise à jour de logiciels de traitement de données.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
Disclosed herein are adapters containing designed ankyrin repeat protein domains fused to peptides, scFv or viral glycoproteins specifically designed to target antigen presenting cells (APCs), such as dendritic cells (DCs). Adenoviruses armed with such adapters efficiently transduce human dendritic cells and can be utilized for therapeutic approaches, such as tumor vaccination or direct delivery of payloads (such as stimulatory cytokines) into lymph nodes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a gutless vector with a minimal replication system. This vector is capable to amplify its own genome within the host cell, but is not able to generate new particles. Advantages of this vector include an increased longevity in dividing cell, an increased payload expression and no lysis of the host cell.
The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
The present invention relates to a method for integrating a cargo nucleic acid molecule into the genome of a cell. For that purpose, the cargo nucleic acid sequence is flanked by 3-nucleotide repetitions of the sequences adjacent to locus of integration, and the cell's own repair mechanism is utilized.
A cryostat for operation with liquid helium, comprises a primary chamber (2) with a main region (4) and a pot region (6) for containing a bath (8) of liquid helium-4, primary inlet means (12) for introducing liquid helium-4 and primary outlet means (14) for releasing gaseous helium-4, the primary inlet means comprising a transfer line (16) extending into the primary region. The cryostat is configured for operation under a continuous supply of liquid helium-4 and at a reduced helium-4 pressure, whereby gaseous helium-4 is pumped off through the outlet means. The primary chamber comprises a baffle structure (18) arranged between the pot region and the main region, the baffle structure defining at least one flowpath (20a, 20b) for the flow of gaseous helium-4, each flowpath forming a detoured connection between the pot region and the main region. A method for operating the cryostat comprises a cool-down phase followed by a stationary phase. In the cool-down phase, liquid helium-4 is supplied from an external reservoir through the primary inlet means into the pot region thereby evaporatingly cooling the latter until a bath of liquid helium-4 starts to accumulate on a bottom surface of the pot region. In the stationary phase, a bath temperature of liquid helium-4 is maintained by regulating the inlet flow of liquid helium-4 and/or regulating the rate of pumping off gaseous helium-4 through the primary outlet means, and optionally by controlled heating.
The invention relates to a device to be used for closing a tissue opening in a tissue. In particular, the present invention relates to a device used for a closing an opening in a membrane such as a fetal membrane by stitching in a minimally invasive procedure.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
A61B 17/42 - Gynaecological or obstetrical instruments or methods
The invention relates to a method for facilitating endosperm development in an angiosperm central cell in absence of karyogamy, or fertilization by a sperm cell. The method according to the invention comprises specifically and selectively inhibiting, or substantially decreasing expression or activity, or lowering the concentration, of RBR1 in the central cell, by cell specific expression of an agent targeting either the expression of the gene encoding RBR1, or by directly or indirectly targeting RBR1 protein through cell-specific expression of an agent leading to degradation of the protein. The invention further relates to a recombinant angiosperm cell having the potential for endosperm development from a central cell in absence of fertilization. A related aspect encompasses a plant comprising such cell, and seed derived therefrom in absence of fertilization.
The invention relates to a computer-implemented method for determining a sleep restoration index indicative of a change of slope of slow waves during a non-REM sleep phase. The method employs a first neural networks for determining and filtering out epileptic spikes in the EEG data and a second neural network for identifying and labeling sleep stages. Combining the information generated by these networks, slow waves are identified and a change of slope of the slow waves is determined. The invention also relates to an EEG system and a computer program configured to executes the method.
A monitoring device for monitoring oxygenation of tissue (31) comprises a near-infrared optical detection unit (100) and a probe unit (40) having a plurality of light emitters (50) directed toward the tissue (31), and at least one light detector (10) receiving light returning from the tissue (31). The probe unit (10) comprises a rigid support structure (1) that carries the plurality of light emitters (50) and/or the at least one light detector (10). The rigid support structure (1) comprises a plurality of positioning sensors (5) for detecting a positioning of the probe unit (10) relative to a tissue surface (30) located above the tissue (31) and several sensor guide elements (3) extending from the support structure (1) and moveably supporting the plurality of positioning sensors (50). The probe unit (10) further comprises a cushion structure (2) that comprises an attachment side (20) attached to the support structure (1) and a contacting side (21), opposite to the attachment side (20), having a compressible surface (22) for contacting the tissue surface (30). The plurality of positioning sensors (5) moveably extend through the cushion structure (2) towards the contacting side (21) of the cushion structure (2).
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
23.
DESIGNED ANKYRIN REPEAT PROTEIN AGENTS TARGETING BRACHYURY AND THEIR USE IN TREATMENT OF CHORDOMA
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Ex vivo tissue culturing and sampling system (2) comprising a microfluidic cartridge (4) and a microfluidic sampling apparatus (3) that receives the microfluidic cartridge and a tissue support substrate (5) on which a tissue sample (1) to be cultured and analysed is mounted, the tissue support substrate separable from the microfluidic cartridge and comprising a porous hydrophilic membrane (19), the microfluidic cartridge comprising - a body (10), - a reaction chamber (20) formed within the body and configured to be sealingly closed by a seal (24) around the tissue sample (1) on the tissue support substrate (5), and - a transparent observation window (16) bounding one side of the reaction chamber configured to allow microscope imaging of the tissue sample, the microfluidic sampling apparatus comprising - a cartridge holder (6) in which the microfluidic cartridge and biological sample support substrate is removably mounted, - a reagent fluid flow system (7) configured to pump liquid through the microfluidic cartridge reaction chamber, and - a gas to liquid diffusion device (8) connected to the reagent fluid flow system upstream of the microfluidic cartridge reaction chamber.
The invention relates to a CjCas9 variant characterized by at least one of the mutations E789K and S951G. The invention further relates to base editing enzymes comprising the Cas variant according to the invention and an adenosine deaminase activity, and to polynucleotides encoding same.
A system and method are provided for visually conveying a physiological state of a patient. For that purpose, a graphical representation of a patient may be established on a display. The graphical representation may be configured to visually convey a current state of the physiological parameter using a set of graphical elements. To further visually convey a future state of the physiological parameter using the graphical representation of the patient, a prediction technique may be used to obtain at least one predicted value of the physiological parameter for at least one future time instance and a modified version of a set of graphical elements may be selected for display based on a predicted value of the physiological parameter. The modified version may be modified by a visual attribute of the set of graphical elements having been modified. For example, a rendering style may be modified. This way, a viewer will recognize a visualized future state in the same manner as that the viewer would recognize a visualized current state, while still being able to distinguish the visualization of the future state from that of the current state.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
27.
IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Spain)
Inventor
Margarit Taule, Josep Maria
Liu, Shih-Chii
Jimenez Jorquera, Cecilia
Abstract
A neurocomputational electrochemical sensing device (1) is proposed for predicting properties of a substance. The device (1) comprises: a plurality of electrochemical sensors constituting a sensor array (3), the sensors being sensitive to sensed attributes advantageous to predict a set of properties of interest of the substance, each sensor being configured to output a sensor output signal indicative of a sensor response of the respective sensor to measurable changes in the sensed attributes of the substance; a readout circuit (5) for biasing the sensors and for conditioning the sensor output signals into readout circuit output signals to facilitate further processing of the sensor responses; and an artificial neural network processor (7) for processing the readout circuit output signals, the processor (7) comprising neurons interconnected by synapses, the processor (7) being configured to output a set of processor output signals whose signal values are indicative of the properties to predict. The sensor array (3) comprises first electrochemical sensors selective to properties correlated with the desired properties to predict, and second electrochemical sensors sensitive primarily to the main interferents of the substance. The neurons and/or the synapses are configured to be trained to compensate for sensor drift and/or cross-sensitivities upon generating the processor output signals.
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.
The invention relates to a method for identifying and quantifying a polypeptide from a library of polypeptides. The method comprises the steps of: 1—providing a polypeptide library and a detection tag library, 2—generating a nested library comprising the polypeptides and the detection tags, 3—sequencing the nested library, 4—selecting a member of the nested library in one or several selection steps that are independent of a physical genotype-phenotype linkage, 5—isolating the detection tag from the selected polypeptide, 6—identifying and quantifying the detection tag by mass spectrometry, 7—obtaining the sequence of the selected polypeptide. The invention also relates to a collection of polypeptides, a collection of detection tags, and a collection of plasmid vectors.
Index creation in a streaming database with medical state parameters allows near-real-time access to medical state parameters reflecting medical states of patients. A message broker receives messages that include records with current measured medical state parameter values of patients. A stream processor processes messages with a plurality of parameter augmentation algorithms to derive additional computed medical state parameter values for a respective patient. Records with the computed values are inserted via generated messages into any incoming data stream. A data handler can create persisted patient-signal specific stream data tables for unknown combinations of patient identifier and signal identifier in the streaming database, and can create a block range index for the time information of the persisted stream data table. Records contained in the received and generated messages are written into respective persisted patient-signal specific stream data tables of the streaming database, and respective block range indexes are updated accordingly.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
The invention relates to immunopeptidome-derived bacterial peptides (IPdBPs), microbe-derived peptides capable of stimulating tumour-associated lymphocytes and eliciting an anti-tumour immune response. The invention further discloses T cell receptors capable of recognizing such peptides in the context of patient HLA. The invention further relates to the use of the peptides and TCRs in treatment of tumour patients.
The invention provides a method of predicting the prognosis of a breast cancer patient by determining the expression level of p53 and GATA in a lymph node metastasis sample. The invention further encompasses pharmaceutical compositions, or methods of treating patients with a good or poor prognosis identified using the above methods, in addition to a kit, or system comprising the means to determine an expression level of p53 and/or GATA3 in a lymph node metastasis sample.
The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
In particular, the present invention relates to a cyclic peptide, wherein said cyclic peptide comprises an amino acid sequence (1), wherein said amino acid sequence (I) comprises the following amino acid sequence: X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-NIS-D16-Q17-K18-K19-L20-C21-X22-X23-X24-C25-X26-X27-X28-X29-X30 (SEQ ID NO: 1), wherein
X1, X2, X3, X5, X6, X7, X9, X10, X11, X22, X23, X24, X26, X27, X28 and X29 are independently of each other an amino acid; C4, C8, C21 and C25 are independently of each other cysteine; P12 is proline; I13 is isoleucine; T14 is threonine; N15 is asparagine; D16 is aspartic acid; Q17 is glutamine; K18 and K19 are independently of each other lysine; L20 is leucine; and X30 is an amino acid or a deletion,
wherein said cysteines C4 and C25 form a first disulfide bond and said cysteines C8 and C21 form a second disulfide bond.
Computer system and computer-implemented method for rendering representations of blood gas state parameters of a patient to support a medically trained person in blood gas analysis of the patient's blood, comprising: receiving, from a data source, time series of sampled measurement values obtained from a plurality of blood gas analysis sensors for the following blood gas state parameters of the patient: Glucose, Chloride, Potassium, Calcium, Sodium, and Hemoglobin; mapping each state parameter to a predefined corresponding graphical representation with each graphical representation for a particular state parameter being distinct from all graphical representations of the remaining state parameters; and rendering, in a virtual 3D tunnel shaped scene representing the inside of an artery, animated visualizations of the graphical representations, in accordance with predefined animation rules, such that respective graphical objects move through the inside of the artery and reflect current values of the respective state parameters.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary products; dietetic substances
and foodstuffs for medical or veterinary use, food for
babies; dietary supplements for humans and animals; herbal
supplements; homogenized food for medical use;
pharmaceutical preparations in the form of tablets,
capsules, sachets, drinkable solutions or suspensions;
parenteral preparations; fats, oils and emulsions for
medical use; biological and chemical reagents for medical or
veterinary use; anti-inflammatories. Infusion sets; intravenous feeding tubes; intravenous
feeding bottles; intravenous catheters. Provision of information on dietary supplements and
nutrition; dietary and nutrition recommendation services,
particularly with regard to parenteral nutrition; services
provided by consultants in the medical, medicinal and
pharmaceutical field; provision of information in the
pharmaceutical field; medical services.
38.
A COMPUTER-IMPLEMENTED METHOD, DEVICE, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR PROCESSING ANATOMIC IMAGING DATA
A computer-implemented method for processing anatomic imaging data, the method comprising, for a plurality of anatomic specimens: acquiring 3D imaging data of a specific body part of an anatomic specimen of the plurality of anatomic specimens; acquiring 2D images of the specific body part of the anatomic specimen from a plurality of different perspectives with respect to the specific body part; determining a plurality of camera matrices P corresponding to the acquired 2D images; generating synthetic 2D images by projecting the acquired 3D imaging data in accordance with the plurality of camera matrices P; and associating the acquired 2D images with one of the synthetic 2D images as training data pairs in accordance with the plurality of camera matrices P and plurality of perspectives. The method further comprising generating a training dataset for use in training an artificial intelligence algorithm using the training data pairs.
The present invention is directed to a method for introducing charged compounds into three-dimensional biological tissues comprising the step of introducing at least one charged compound of interest into the biological tissue, wherein a composition for dissolving and removing lipids and/or a composition for introducing at least one charged compound of interest into the bio- logical tissue is injected into the biological tissue and a pulsed electrical field (PEF) is applied to the biological tissue. The invention further relates to a device for use in this method, and a use of this method or this device for histological staining.
The invention relates to a dye molecule described by a general formula (I) or (I-A), wherein R1and R2, R3, R4, R5, R6πππ-electron system of formula (I) by a double bond.
C09B 23/06 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups three CH groups, e.g. carbocyanines
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
41.
METHODS OF TUMOUR THERAPY WITH A COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES
The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Commissariat à l'Energie Atomique et aux Energies Alternatives (France)
Universität Zürich (Switzerland)
Inventor
Moro, Filippo
Vianello, Elisa
D'Agostino, Simone
Indiveri, Giacomo
Payvand, Melika
Abstract
The present disclosure relates to a neural network comprising a first synapse circuit (106) configured to apply a first time delay to a first input signal (READ1) using a first resistive memory element (108) and to generate a first output signal at an output of the first synapse circuit by applying a first weight to the delayed first input signal; and a second synapse circuit (106) configured to apply a second time delay, different to the first time delay, to the first input signal, or to a second input signal (READN), using a second resistive memory element (108) and to generate a second output signal at an output of the second synapse circuit by applying a second weight to the delayed second input signal.
Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
Basilea Pharmaceutica International AG, Allschwil (Switzerland)
UNIVERSITÄT ZÜRICH (Switzerland)
Inventor
Obrecht, Daniel
Luther, Anatol
Upert, Grégory
Desjonqueres, Nicolas
Brabet, Emile
Zbinden, Peter
Zerbe, Oliver
Möhle, Kerstin
Abstract
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a medical system (20) for measuring visual evoked potentials (VEP) of a person, comprising a display (2) for displaying images to be observed by the person with a single eye, and an image generating module (1), the image generating module (1) being configured to cause the display (2) to display a sequence of images comprising a first image and a second image. The medical system (20) further comprises: a plurality of electrodes (3) configured to be attached to the scalp of the person and to detect EEG signals indicative of electrical activity in the brain of the person in response to observing said sequence of images displayed by the display (2), an EEG recording module (4) connected to said plurality of electrodes (3), the EEG recording module (4) being configured to record said EEG signals, and an analyzing module (8), the analyzing module (8) being configured to derive from said EEG signals recorded by the EEG recording module (4) at least one visual evoked potential (VEP).
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
The invention relates to a hydroxycarboxylic acid of the formula CH3(CH2)8 CHOH—(CH2)—CO2H or a pharmaceutically acceptable salt thereof, for use as a medicament, particularly for use in the treatment or prevention, including prevention of recurrence, of cancer, for example colorectal cancer. The invention further relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a hydroxycarboxylic acid as specified herein, and another antineoplastic treatment. Further aspects of the invention relate to a method of measuring the presence of a hydroxydicarboxylic acid of the formula HO2C(CH2)7 CH2CHOH—(CH2)—CO2H, or CH3(CH2)10COOH to predict or to monitor the clinical outcome of a cancer patient, and/or to predict or monitor the response to an antineoplastic therapy or treatment with live bacteria.
C07C 53/126 - Acids containing more than four carbon atoms
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention relates to a chimeric cytokine receptor and its use in switching the polarisation of macrophages or monocytes from M2 to M1. The present invention also relates to a method for monocyte modification to selectively increase the phagocytotic activity and to modulate the polarisation of offspring macrophages.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
49.
COMPLEMENT COMPONENT 7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
The present invention relates to a method for predicting the likelihood of developing, or of diagnosing, a systemic post-infection syndrome via measuring the amount of C7 in a patient sample, particularly the amount of liquid-phase (soluble) or complexed C7. The invention particularly relates to the diagnosis of long COVID. The invention further relates to a treatment or prevention of a systemic post-infection syndrome via administering to a patient an agent able to mimic or modulate the biological activity of C7.
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
Rotating tissue culture insert (20, 40) for the position inside a rotatable roller bottle (100) partially filled with a liquid for the cultivation of cells comprising a scaffold (11) provided for the cultivation of cells, characterized in that the rotating tissue culture insert (20) comprises an axle body (3) and at least two protrusions extending in radial direction from the axle body (3), wherein the protrusions (4) define wheels of said rotating tissue culture insert (20) with a runway that is in contact with the surface (25) of a roller bottle (100) when the roller bottle (100) is in a lying position.
The invention relates to a method for identifying a variant of a biomolecule among a plurality of variants of the biomolecule by these steps: A) Acquiring a fluorescence intermittence signal pattern for each variant. Each of the variants is labelled with a blinking fluorophore. B) Determining a fluorescence intermittency signal characteristic for each variant. C) Labelling at least one variant of the biomolecule in a sample with the fluorophore, and acquiring its fluorescence intermittency signal. D) Determining a presence of at least one fluorescence intermittency signal characteristic as determined in step B) in the acquired fluorescence intermittency signals from the sample. E) Establishing the presence, the quantity and/or localisation, of at least one variant of the biomolecule in the sample based on the fluorescence intermittency signal characteristic.
Provided are methods of obtaining a mass culture of muscle derived muscle precursor cells (MPCs) using microcarriers as growth substrate, methods for obtaining a therapeutic efficient amount of those cells, a cell population obtained by said methods as well as compositions comprising the expanded cells and methods for preparing a medicament, for example, for use in the treatment of skeletal muscle dysfunctions.
In one aspect, the invention relates to the use of difluoromethylornithine (DFMO) in treatment of cancer. The drug is administered to a patient undergoing a dietary regimen and/or drug treatment that is designed to reduce a plasma level of proline, arginine, or both.
The present invention relates to the production of skin substitutes with a defined ratio of blood endothelial cells (BEC), to lymphatic endothelial cells (LEC), and their use in medicine.
The invention relates to protein fragments of human myelin basic protein (MBP) and nucleotide sequences encoding any thereof, for use in the treatment, diagnosis and/or prevention of multiple sclerosis (MS). More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.
The present invention relates to a bispecific antibody comprising at least a first binding domain and a second binding domain, wherein said first binding domain binds to an organic fluorophore and wherein said second binding domain binds to CD3, and to a combination thereof with a labelled binding agent that binds specifically to a target antigen, wherein the labelled binding agent is labelled with an organic fluorophore.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed herein are designed ankyrin repeat domain specifically binding to fibroblast activation protein (FAP). Such designed ankyrin repeat domains can be used in recombinant adapter molecules that are displayed on adenoviruses. Adenoviruses armed with such adapters efficiently transduce human fibroblasts and significantly broaden treatment opportunities through paracrine delivery of cargo to the tumor microenvironment (TME).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
The present invention relates to a composition for use in treating a condition of the lower gastrointestinal tract, e.g. ulcerative colitis, wherein the composition comprises: a) a carrier comprising: a1) water in an amount of more than 10% to 30% by weight of the carrier; and a2) monoacylglycerol lipid in an amount of 70% to 90% by weight of the carrier, wherein the monoacylglycerol lipid comprises monolinolein or monoolein, or combinations thereof; and b) a pharmaceutically active agent, wherein the composition forms a lipid cubic phase at a temperature of 36 °C to 39 °C. The composition is particularly suitable for rectal administration, for example, as an enema. Also disclosed is a composition, methods for preparing the compositions, and kits for making the compositions.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
62.
LIPID EMULSION WITH ANTI-INFLAMMATORY EFFECTS FOR TOTAL PARENTERAL AND ENTERAL NUTRITION
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media
64.
LIPID EMULSION WITH ANTI-INFLAMMATORY EFFECTS FOR TOTAL PARENTERAL AND ENTERAL NUTRITION
The present invention relates to a lipid emulsion for total parenteral and enteral (oral or through gastric or duodenal tubes) nutrition. The lipid emulsion has advantageous immuno-modulating, anti-inflammatory, and anti-diabetic effects. The lipid emulsion may also comprise a pharmaceutical drug, can be used as a detoxifier, or for reversing negative effects from ischemia-reperfusion injury.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
65.
ADENOVIRAL-BASED IN SITU DELIVERY OF BISPECIFIC T CELL ENGAGERS
Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to direct expression of the BiTE's in situ, i.e. directly at the site at which the BiTE's exert their action. The non-oncolytic viruses are useful in the treatment of diseases such, as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided is an injection device [1] for injection of a substance with an syringe [14] into an organism [20], comprising a holding unit [2], which is adapted to hold the syringe [14], an actuating unit [3], which is adapted for dosed injection of the injection substance and which is removably coupled to the holding [2] unit and couplable with the syringe [14] when the holding unit [2] holds the syringe [14], a needle guide [8] which is adapted to be removably couplable with an injection needle [11] and for changing the injection position of the injection needle [11]; and a connection structure [12] which connects the holding unit [2] and the needle guide [8].
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations for treatment of inflammatory, diabetic, immunological, and neurological conditions; dietetic enteral and parenteral formulations, namely, emulsions for medical or veterinary use; food for babies; dietary supplements for humans and animals; herbal supplements; homogenized food adapted for medical use; pharmaceutical preparations in the form of tablets, capsules, sachets, drinkable solutions or suspensions for treatment of inflammatory, diabetic, immunological, and neurological conditions; parenteral preparations for treatment of inflammatory, diabetic, immunological, and neurological conditions; edible fats, oils and lipid emulsions for medical use; biological and chemical reagents for medical or veterinary use; anti-inflammatories Infusion sets; intravenous feeding tubes; intravenous feeding bottles; intravenous catheters Provision of information about dietary supplements and nutrition; dietary and nutrition recommendation services, particularly with regard to parenteral nutrition; medical consultation and treatment of inflammatory, diabetic, immunological, and neurological conditions and pharmaceutical consultation; provision of pharmaceutical information; medical services
68.
DIRECTED EVOLUTION OF MEMBRANE PROTEINS IN EUKARYOTIC CELLS WITH A CELL WALL
The invention relates to a method for selecting an expressed sequence from a library, comprising the following steps: Each of a plurality of eukaryotic cells comprising a cell wall comprises a nucleic acid sequence member of a library, which is expressed as a target membrane protein in said eukaryotic cells. The cell wall of the cells is permeabilized. The penneabilized cells are labeled with a ligand capable of binding to the target membrane protein. The ligand bears a detectable label. A subset of the labelled cells is selected as a function of detectable label present. Finally, an expressed nucleic acid sequence is isolated from said selection of cells in an isolation step.
The invention relates to a method, particularly a computer-implemented method for determining a fatigue value of a person, the method comprising the steps of: i) displaying of: c) a first group (1) of symbols and a second group (2) of symbols, d) a selection rule (3) associating each of the symbols of the first group (1) of symbols to one symbol of the second group (2) of symbols, ii) highlighting one symbol (11) of the first group (1) of symbols, iii) receiving a user input from the person selecting one symbol (12) of the second group (2) of symbols, iv) determining a truth value based on the selected symbol (12) of the second group (2) of symbols, wherein the truth value assumes a true value if the selected symbol (12) is selected in accordance with the selection rule (3) and wherein the truth value takes on a false value if not, wherein the highlighted symbol (11) of the first group (1) of symbols is highlighted for a predetermined time based on a statistical response time of the person, and wherein if the user input is not received within the predetermined time in step iv), the method is set forth with step v) having the truth value set to the false value, or the method is set forth with step vi), v) storing the truth value on a non-transitory memory device, vi) changing the selection rule (3), such that each of the symbols of the first group (1) of symbols is associated anew to one symbol of the second group (2) of symbols, vii) changing the highlighted symbol (11) of the first group (1) of symbols, viii) repeating steps iii) to vii) at least once and ix) based on at least some of the stored truth values, determining a fatigue value of the person.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
70.
DESALINATION AND/OR PURIFICATION DEVICE, DESALINATION AND/OR PURIFICATION CARBON MEMBRANE, AND METHOD OF DESALINATING AND/OR PURIFYING A LIQUID
King Abdullah University of Science and Technology (Saudi Arabia)
Universität Zürich (Switzerland)
Inventor
Cruz, Aluizio M.
Fratalocchi, Andrea
Bonifazi, Marcella
Mazzone, Valerio
Aegerter, Christof
Abstract
The present invention relates to a desalination and/or purification device, a desalination and/or purification carbon membrane, and a method of desalinating and/or purifying a liquid by using such a desalination and/or purification device. In various illustrative embodiments, a desalination and/or purification device is provided, the desalination and/or purification device comprising a carbon membrane body comprising a carbon surface, and a structure of microchannels and/or nanochannels at least partially permeating the carbon membrane body and ending at openings at the carbon surface, a liquid transportation structure extending at least partially through the carbon membrane body without being exposed at the carbon surface, and a condenser arranged above the carbon membrane body. The liquid transportation structure is arranged and configured to supply the structure of microchannels and/or nanochannels of the carbon membrane body with a liquid to be desalinated and/or purified and the structure of microchannels and/or nanochannels of the carbon membrane body may be an at least two-level disordered network of channels.
Present invention relates to dexmedetomidine or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a sleep disorder in a subject, wherein dexmedetomidine or its salt is to be administered to a subject via transmucosal administration route in a dose of between 10 mcg and 120 mcg. Said dexmedetomidine or a pharmaceutically acceptable salt thereof is preferably formulated as an orodispersible tablet and is particularly useful in the treatment of insomnia.
Provided herein is a cyclic tetrapeptides including alternating α- and 3-amino acids and metal complexes thereof. The cyclic tetrapeptides are useful for coordinating a metal selected from Pb, Cd, Hg and As. Also provided herein is the use of the cyclic tetrapeptides in treating a disease, particularly metal poisoning, and the use in remediation of contaminated water and soil. Also provided herein are methods for detecting said metals in various substrates are provided.
The invention relates to a method of obtaining a variant of a T cell epitope peptide expressed in the tumour of cancer patient, wherein the variant is characterised by targeted amino acid substitutions conferring an improved capacity to stimulate CD8+ and CD4+ T cells. The invention further relates to vaccine and, pharmaceutical compositions comprising variant T cell epitope peptides and their use in treating cancer.
141313131316144)-NRN1RN2, OH, CN, halogen, NRN1RN222RSwith RN1, RN2, and RS133 alkyl, n is 0, 1, 2, 3 or 4, each R1166 alkyl, OH, ORO, COORA22, halogen, NRN1RN222RS, with RN1, RN2, RS, RA, and RO1648288 heterocycle, particularly two R156566 heterocycle, wherein the cyclo-alkyl or the heterocycle is unsubstituted or substituted with OH, COORA, ORO CN, halogen, NRN1RN222RSwith RN1, RN2, RO, RA133 alkyl, m is 0, 1, or 2, and each R21322, CN, and halogen. The compound is used as a medicament, in particular for use in treatment or prevention of cancer.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/428 - Thiazoles condensed with carbocyclic rings
76.
RIBOSOMAL PROTEIN S15 IN CRISPR TRANSPOSON MEDIATED SEQUENCE ENGINEERING
The invention relates to an engineered nucleic acid targeting system for insertion of a donor polynucleotide sequence into a target DNA strand, comprising: - one or more CRISPR-associated transposase proteins or functional fragments thereof; - a Cas protein; - a guide RNA molecule capable of complexing with the Cas protein and directing sequence specific binding of the guide-Cas protein complex to a target sequence of a target DNA strand; and - a ribosomal protein S15. Any of the protein components may be provided encoded by a nucleic acid sequence. A further aspect of the invention relates to a method for inserting a cargo DNA nucleic acid sequence into a target nucleic acid DNA sequence by the system of the invention. Another aspect of the invention relates to the use of a recombinant ribosomal protein S15, in a method for inserting a donor polynucleotide sequence into a target polynucleotide sequence, said method for inserting being facilitated by a CRISPR-associated transposase system.
The present invention relates to the use of neocuproine, elesclomol, disulfiram and/or dithiocarbamate for use in treatment of cancer, optionally in combination with MAPK-pathway inhibitors in cancers carrying mutations that are recognized as MAPK-pathway activating mutations.
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This document provides various technical improvements for performing optical NIRS measurements using an optical sensor. The revelation concerns A) a specific measurement method, B) a specific cable design for such a sensor, C) a light shielding cover to be used with such a sensor, and D) a specific internal light shielding to be used inside the sensor. All of these aspects can be used for improving the accuracy and robustness of the optical measurements to be performed with the sensor (cf. Fig. A1).
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
79.
LIGANDS TO GM-CSF OR GM-CSF-RECEPTOR FOR USE IN LEUKEMIA IN A PATIENT HAVING UNDERGONE ALLO-HCT
Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
80.
AGENTS FOR TREATMENT OF ENDOMETRIOSIS AND OTHER BENIGN GYNECOLOGICAL NEOPLASMS
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present invention relates to agents for the treatment and/or diagnosis of endometriosis and other benign gynecological neoplasms disease or disorder and also relates to agents capable of eliciting a cytotoxic response in benign gynecological neoplasms diseases or disorders.
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The invention provides a human IL-2 (hlL-2)-specific monoclonal antibody, wherein a complex of hlL-2 and the monoclonal induces IL-2 signalling preferentially via CD25 and the trimeric IL-2R. The invention further provides a pharmaceutical composition comprising hlL-2 and said hlL-2-mAb for use treating inflammatory disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Disclosed herein are recombinant adenoviruses, recombinant proteins and trimeric proteins that are useful for the transduction of immune cells, such as T cells or NK cells. The present invention provides a versatile and highly specific system that is useful for numerous purposes, including the development of novel therapeutic approaches. The present invention makes use of specially designed adapter molecules that enable the specific targeting of immune cells, such as T cells or NK cells, which strongly increases transduction efficiencies, in particular for in vitro transduction of immune cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an ex vivo method and means for determining the risk estimate of side effects of a drug and/or probability estimate of drug response in a subject, the method comprising collecting the mass spectra of substances present in the exhaled breath and analyzing the mass spectra using a previously trained mathematical model. The instant methods and means are particularly useful in therapeutic drug monitoring, determining the risk estimate of side effects of a drug, determining the probability estimate of drug response in the subject, and determination of subject compliance.
The present invention relates to a method for ex vivo antibody diversification, making use of a protein-RNA complex comprising an activation-induced cytidine deaminase (AID), a nuclease dead Cas9 (dCas9) or nickase Cas9 (nCas9), transcription activator VP64; and one or more single-guide RNAs (sgRNA).
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Digital notepads, electronic albums, diaries; downloadable
electronic data and publications; downloadable podcasts;
electronic newsletters; scientific instrumentation;
software, application software for mobile telephones and
tablets; software for data and document capture,
transmission, storage and indexing. Collection of psychological data on development for
scientific purposes; collection, systematization and
recording of data in a computer database. Education; training, sporting and cultural activities;
preparation and hosting of conferences, congresses,
seminars, symposiums, lectures, lessons and training
courses; online publication of electronic books, newsletters
and newspapers.
87.
VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA
The present invention provides novel viral vectors for use in human therapy, particularly for use in in the treatment of a disease or disorder which has its origin in the brain or is brain based, particularly a PGRN-associated neurodegenerative disease or disorder including frontotemporal degenerative disease or disorder such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The invention also provides viral vectors for use in the treatment of brain tumors, particularly brain tumors selected from the group consisting of glioblastoma, glioma, ganglioneuroblastoma, astrocytoma, oligodendroglioma, PNET (primitive neuroectodermal), medulloblastoma, CNS lymphoma, and neuroblastoma, or any other CNS tumor and further in the treatment of brain metastasis, originating from any forms of breast, lung, colon, testicular, renal carcinomas and melanoma, or any other solid tumor, and any hematologic tumor, comprising all forms of leukemia and lymphomas. Further, the viral vectors may be used in the treatment of autoimmune diseases, inflammatory diseases and/or allergic diseases.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and/or co-stimulated by pre- and/or co-incubation with said transduction enhancing compound or a combination of transduction enhancing compounds prior to and/or during contacting the target cell with the retroviral vector.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
89.
STABILIZING N-CAP SEQUENCES FOR ARMADILLO REPEAT PROTEINS
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
90.
SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer treatment or prevention.
The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. The monomer comprises a backbone having 2 to 6 elements, wherein at least one element is —CH(R)— or —N(R)—. R is a moiety -E-H, -L-(NH2)m or a moiety of formula 1, with E, L, R1 and R2 being defined as described in the present specification. The monomer comprises at least one —I to allow detection via X-ray and at least one —NH2 to allow crosslinking. Furthermore, the monomer comprises polar functional groups that contribute to water solubility. To avoid extravasation and glomerular filtration, the polymers are pre-crosslinked before the vasculature of a tissue, an organ or whole animal is perfused. After perfusion, the pre-crosslinked contrast agent is further crosslinked to be retained within the tissue, organ or animal permanently.
C07C 233/55 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
93.
CONTAINER FOR THE STORAGE AND MRI ANALYSIS OF BRAINS IN PATHOLOGY
The present invention relates to a container (1) for storing a human or animal brain (2), comprising: a plurality of layers, the layers (10, 20, 21, 30) being configured to be stacked on top of one another, wherein said plurality of layers comprises a bottom layer (10), a top layer (30) and optionally also intermediary layers (20, 21) configured to be arranged between the bottom and the top layer (10, 30), and wherein the layers (10, 20, 21, 30) form a cavity (3) for accommodating the brain (2) when being stacked on top of one another. Furthermore, a coordinate system is integrated into the container (1) and the container (1) can serve as a tool for correlating MRI and histology.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 16/00 - Devices specially adapted for vivisection or autopsy
Disclosed herein is an adenoviral vector system utilizing DARPin adapters. The system is highly effective, safe and able to deliver DNA in a cell-specific manner. It is demonstrated that the system is unexpectedly versatile, and can be used in conjunction with protein scaffolds, bioactive peptides and small molecules. This makes the system useful for numerous purposes, including the use of the system for therapeutic and diagnostic purposes.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12N 15/62 - DNA sequences coding for fusion proteins
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
Computer system (100) and method for index creation in a streaming database (130) with medical state parameters of different types associated with a plurality of patients (10) is provided to allow near-real-time access to medical state parameters reflecting medical states of patients. A message broker (110) receives messages in one or more incoming data streams (30). The messages include records with current measured medical state parameter values (11-1) of patients. A stream processor (120) processes incoming messages with a plurality of parameter augmentation algorithms (PAA1 to PAAn) wherein each parameter augmentation algorithm is adapted to derive additional computed medical state parameter values for the respective patient. Records with the computed values are then inserted via generated messages (mg*) into any incoming data stream. A data handler (140) can create persisted patient-signal specific stream data tables for yet unknown combinations of patient identifier and signal identifier in the streaming database (130), and can further create a block range index for the time information of said persisted stream data table. Records contained in the received and generated messages (m*, mg*) are then written into respective persisted patient-signal specific stream data tables (SDT-P2-S1 to SDT-P2-Sn) of the streaming database (130), and the respective block range indexes are updated accordingly upon record insertion.
The invention relates to a device to be used for closing a tissue opening in a tissue. In particular, the present invention relates to a device used for a closing an opening in a membrane such as a fetal membrane by stitching in a minimally invasive procedure.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
100.
SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
